Corum Group announces $3.3 million investment from Arrotex.
Generic and private label OTC company Arrotex will take 60 million shares in listed pharmacy software specialist Corum Group, as part of a capital raising which will inject $3.3 million into the business.
Arrotex Executive Chairman, Dennis Bastas, will join the Corum Board, with the funding to be used to “accelerate key product development and business expansion”.
More in today’s issue of Pharmacy Daily.